1. Home
  2. TCI vs TLSI Comparison

TCI vs TLSI Comparison

Compare TCI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Transcontinental Realty Investors Inc.

TCI

Transcontinental Realty Investors Inc.

HOLD

Current Price

$38.17

Market Cap

308.7M

Sector

Finance

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.51

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCI
TLSI
Founded
1983
2010
Country
United States
United States
Employees
N/A
102
Industry
Real Estate
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
308.7M
270.2M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
TCI
TLSI
Price
$38.17
$4.51
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
3.3K
137.9K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
135.29
N/A
EPS
1.60
N/A
Revenue
$49,060,000.00
N/A
Revenue This Year
N/A
$35.45
Revenue Next Year
N/A
$37.58
P/E Ratio
$22.99
N/A
Revenue Growth
4.23
N/A
52 Week Low
$27.06
$3.42
52 Week High
$59.65
$7.95

Technical Indicators

Market Signals
Indicator
TCI
TLSI
Relative Strength Index (RSI) 50.07 54.33
Support Level $33.50 $4.28
Resistance Level $42.76 $4.83
Average True Range (ATR) 1.22 0.23
MACD -0.05 0.03
Stochastic Oscillator 33.38 58.14

Price Performance

Historical Comparison
TCI
TLSI

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: